



© The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. First published online 5 March 2021

The Nutrition Society Winter Conference Live 2020 was held virtually on 8–9 December 2020

Conference on ‘Micronutrient malnutrition across the life course, sarcopenia and frailty’ Symposium four: Micronutrient malnutrition and addressing the issues

Sex differences in requirements for micronutrients across the lifecourse

Ann Prentice^{1,2}

¹Medical Research Council Nutrition and Bone Health Group, Clifford Allbutt Building, University of Cambridge, Hills Road, Cambridge, CB2 0AH, UK

²Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, PO Box 273, The Gambia

For many people, micronutrient requirement means the amount needed in the diet to ensure adequacy. Dietary reference values (DRV) provide guidance on the daily intake of vitamins and minerals required to ensure the needs of the majority in the population are covered. These are developed on estimates of the quantity of each micronutrient required by the average person, the bioavailability of the micronutrient from a typical diet and the interindividual variability in these amounts. Sex differences are inherent in the requirements for many micronutrients because they are influenced by body size or macronutrient intake. These are reflected in different DRV for males and females for some micronutrients, but not all, either when data from males and females are combined or when there is no evidence of sex differences. Pregnancy and lactation represent times when micronutrient requirements for females may differ from males, and separate DRV are provided. For some micronutrients, no additional requirement is indicated during pregnancy and lactation because of physiological adaptations. To date, little account has been taken of more subtle sex differences in growth and maturation rates, health vulnerabilities and *in utero* and other programming effects. Over the years, the MRC Nutrition and Bone Health Group has contributed data on micronutrient requirements across the lifecourse, particularly for calcium and vitamin D, and shown that supplementation can have unexpected sex-specific consequences that require further investigation. The present paper outlines the current issues and the need for future research on sex differences in micronutrient requirements.

Calcium: Dietary reference values: Micronutrients: Vitamin D

Micronutrient requirements

The term ‘requirement’ has several meanings in nutritional science and these are often used interchangeably, especially when discussing micronutrients. The biological requirement refers to the amount of a nutrient required

by the body for essential structural and metabolic functions. The dietary requirement refers to the amount of the nutrient in a typical diet that supplies sufficient of the nutrient to meet the biological requirement, and, when applied to a population, is the amount of the nutrient in a typical diet that supplies sufficient of the nutrient

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMC, bone mineral content; BMD, bone mineral density; DRV, dietary reference values; IoM, Institute of Medicine; RNI, reference nutrient intake.

Corresponding author: Ann Prentice, email ann.prentice@mrc-lmb.cam.ac.uk

Table 1. Criteria used in developing dietary reference values for eleven micronutrients: adults and children

	UK*	USA/Canada†	EU‡	Factor§
Adults				
Avoidance of risk of deficiency (clinical signs, biomarker threshold)	B ₁₂ , C, D**	Riboflavin, B ₁₂ , C, D††	Riboflavin, folate, B ₁₂ , D	x
Factorial method: (retention/turnover + obligatory losses)	A, iron, calcium, potassium,	A, iron	A, C, iron	Body size
Balance/depletion–repletion studies (using biomarkers, energy intake)	Folate, magnesium,	Thiamin, folate, calcium††	Thiamin, calcium	Body size
Usual intake or biomarker status	Riboflavin	Potassium‡‡	Magnesium	Body size
Intake of energy/protein	Thiamin			Body size
Optimisation of function/health (other than frank deficiency)			Potassium	x
Children				
Interpolation: infant breast-milk intake and adult value (using reference weights)	A, riboflavin, folate, B ₁₂ , C, iron, magnesium	C	C	Body size
Extrapolation: adult values (using reference weights or metabolic weight × growth factor)		A, thiamin, riboflavin, folate, B ₁₂ , magnesium	Riboflavin, folate, B ₁₂ , potassium	Body size
Extrapolation: from adult value (using energy/protein intake)	Thiamin		Thiamin	Body size
Factorial method: (retention/turnover + obligatory losses)	Calcium, potassium	Iron, calcium††	A, iron, calcium	Body size
Usual intake		Potassium‡‡	Magnesium	Body size
Same value as adults	D**	D††	D	x

* Developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾, unless otherwise stated.

† Developed and published by the Institute of Medicine in a series 1997–2001^(4–7), unless otherwise stated.

‡ Developed and published by the European Food Safety Authority in a series 2013–2017⁽¹⁰⁾.

§ Indicates whether body size is an intrinsic factor of the criterion.

** Published by the Scientific Advisory Committee on Nutrition 2016⁽³⁾.

†† Developed and published by the Institute of Medicine 2011⁽⁸⁾.

‡‡ Developed and published by the National Academies of Sciences, Engineering, and Medicine 2019⁽⁹⁾.

to meet the needs of the majority of the population for which the guidelines are set. In the UK this latter definition is referred to as the reference nutrient intake (RNI), in the USA/Canada as the RDA and in the EU as the population reference intake. Where there is insufficient evidence to determine a population dietary requirement for any nutrient, a value referred to as a safe intake in the UK or as an adequate intake in USA/Canada and EU is estimated. These values are known generically as dietary reference values (DRV) in the UK and EU and as dietary reference intakes in the USA/Canada. Most other national authorities developing dietary requirements for their populations use similar terminology, but often with subtle differences. For clarity in this paper, the terms RNI and DRV will be used to denote these various population terms except when referring to a specific set of national reference values, and the discussion will be limited to these three sets of DRV guidelines.

Development of dietary reference values

The definition and methods used to derive DRV are described in detail elsewhere⁽¹⁾. In brief, those for micronutrients are generally based on an estimate of an average biological requirement, an allowance for the bioavailability of the micronutrient from a diet typical of the population, and consideration of the variability of requirement between individuals, in order to derive an RNI that covers the needs of the majority (generally 97.5%) of the population. Most DRV are developed

separately for males and females, and for different ages in bands and, for females, by reproductive status.

The current micronutrient DRV for the UK population were first developed using these principles by the Committee on Medical Aspects of Food Policy and published in 1991⁽²⁾. Since that time, those for vitamins A, vitamin D, folate, calcium, sodium, iron, selenium and iodine have been reassessed by the Committee on Medical Aspects of Food Policy and its successor, the Scientific Advisory Committee on Nutrition, to take account of emerging research. However, new evidence did not lead to any revision of the DRV for these micronutrients, except for those for vitamin D, published in 2016⁽³⁾. The Institute of Medicine (IoM) undertook the derivation of micronutrient dietary reference intakes for USA/Canada, published in a series of volumes from 1997 to 2001^(4–7), with revised values for calcium and vitamin D in 2011⁽⁸⁾ and for sodium and potassium in 2019⁽⁹⁾. More recently, and consequently with a much larger evidence-base to call on, the European Food Safety Authority developed DRV for the EU in a rolling series of assessments for all the micronutrients, summarised in a Technical Report in 2017 (with an update in 2019 for sodium and chloride)⁽¹⁰⁾.

Although there are subtle differences between the DRV developed by each of these three national authorities, the criteria on which they are based are remarkably similar. Table 1 provides, as an illustration, the criteria on which the DRV for eleven of the micronutrients were based for adults. These criteria fall into five main

Table 2. Criteria used in developing dietary reference values for eleven micronutrients: increments for pregnancy and lactation

	UK*	USA/Canada†	EU‡
Pregnancy			
Fetal growth, maternal tissues, pregnancy outcomes	A, riboflavin, folate, C	A, thiamin, riboflavin, folate, B ₁₂ , C, iron, magnesium	A, riboflavin, B ₁₂ , C
Biomarkers in controlled studies			Folate
Usual intake		Potassium§	
Adaptation or offset (i.e. no increment)	Thiamin, B ₁₂ , D**, iron, calcium, magnesium, potassium	Calcium††, D††	Thiamin, D, iron, calcium, magnesium, potassium
Lactation			
Breast-milk concentration + volume	Riboflavin, folate, B ₁₂ , C, calcium, magnesium	A, thiamin, riboflavin, folate, B ₁₂ , C, iron	A, riboflavin, folate, B ₁₂ , C, potassium
Usual intake		Potassium§	
Adaptation or offset (i.e. no increment)	Thiamin, D**, iron, potassium	D††, calcium††, magnesium	Thiamin, D, iron, calcium, magnesium

* Developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾, unless otherwise stated.

† Developed and published by the Institute of Medicine in a series 1997–2001^(4–7), unless otherwise stated.

‡ Developed and published by the European Food Safety Authority in a series 2013–2017⁽¹⁰⁾.

§ Developed and published by the National Academies of Sciences, Engineering, and Medicine 2019⁽⁹⁾.

** Published by the Scientific Advisory Committee on Nutrition 2016⁽⁸⁾.

†† Developed and published by the Institute of Medicine 2011⁽⁶⁾.

categories: (1) the amount of the micronutrient required to avoid the risk of deficiency, as defined by clinical signs or an accepted biochemical threshold; (2) the calculated amount of the micronutrient retained or turned over by the body plus any obligatory losses; (3) empirical data from balance or depletion–repletion studies, often based on biomarker assessments; (4) estimations of usual intake of assumed healthy people in the population, sometimes based on biochemical status markers and (5) the usual intakes of energy or protein, for those micronutrients required for the metabolism of those macronutrients. A sixth category, mooted strongly in the past 20 years, is an amount of the micronutrient that optimises function and health, at intakes above that needed to avoid overt deficiency. To date, however, a criterion of optimal health and disease risk reduction has only rarely been used for DRV development. This is discussed later for calcium and vitamin D.

Sex differences in micronutrient requirements and dietary reference values

For the majority of micronutrients, the selected criterion for the biological requirement includes a component that is related to body size (Table 1), and because, on average, males and females differ in size, this automatically introduces the likelihood that adult micronutrient requirements differ by sex, and therefore that sex-specific DRV would be provided. However, relatively few of the adult DRV for vitamins and minerals developed by the Committee on Medical Aspects of Food Policy, IoM and European Food Safety Authority differ between men and women, and for those that do, this is mainly because the DRV were developed on the basis of the requirement expressed per unit body weight, or per intake of energy or protein. In such instances, the DRV for men is higher than for women when expressed on a unit weight daily basis, e.g. thiamin DRV when expressed in mg/d rather than mg/MJ. For a few

micronutrients, the DRV for adult women is greater than that for men at certain ages, the most notable example being iron, which is higher in premenopausal women than men to cover losses during menstruation. The specific case of sex differences in requirements for calcium is discussed more fully later.

Similar considerations apply to children and adolescents. Micronutrient requirements for children and adolescents are generally based on those for adults with adjustments made for body size at each age (Table 1). For some micronutrients in the UK, an interpolation is made between the intake of the micronutrient from breast-milk in infancy and adult intake, using reference weight data to make allowance for size at different ages. In other instances, this is achieved by back extrapolation from adult values based on *pro rata* calculations, using median weights from reference data or, for some micronutrients in the USA/Canadian guidelines, metabolic weight (weight^{0.75}) and a growth factor derived from the protein requirements for growth e.g.⁽⁴⁾. The differences in body size between boys and girls throughout childhood and adolescence would indicate that there are sex differences in the dietary requirements for most micronutrients. However, as for adults, different DRV for boys and girls are only provided for some micronutrients, and often only for adolescence.

Pregnancy and lactation are times when sex differences in micronutrient dietary requirements would be anticipated because of the biological requirements for fetal growth and breast-milk production. An increment to the DRV for adolescent girls and premenopausal women is provided for some micronutrients to allow for these additional requirements, thereby adding to the sex differences in DRV. Where increments are provided (Table 2), these are based, in pregnancy, on fetal size or maternal tissue expansion and, in lactation, on the micronutrient content of breast-milk plus the breast-milk intake of breast-fed infants. However, for some micronutrients, there is evidence that such increments are not

<p>All ages</p> <p>All cause mortality</p> <p>Immune modulation, asthma, atopic disorders</p> <p>Autoimmune diseases:</p> <ul style="list-style-type: none"> Diabetes type 1 Inflammatory bowel and Crohn's disease Multiple sclerosis Rheumatoid arthritis Systemic lupus erythematosus <p>Susceptibility to infection:</p> <ul style="list-style-type: none"> Tuberculosis Respiratory infections, influenza, COVID-19 <p>Pregnancy/lactation</p> <ul style="list-style-type: none"> Pregnancy-induced hypertension Pre-eclampsia/eclampsia Premature birth Birth outcomes Breastmilk composition 	<p>Fetal life/infancy</p> <p>Poor organ development</p> <p>Lifelong programming:</p> <ul style="list-style-type: none"> Inflammatory and autoimmune diseases Cognitive and psychological development <p>Childhood/adolescence</p> <ul style="list-style-type: none"> Failure to thrive Muscle weakness, mobility Puberty, breast development <p>Older people</p> <ul style="list-style-type: none"> Muscle weakness, falls Cognitive function, depression, dementia Autism, schizophrenia Cardiovascular diseases, hypertension Diabetes type 2, metabolic syndrome, obesity Age-related macular degeneration Oral health and periodontal disease Cancers
---	---

Fig. 1. (Colour online) Non-skeletal health outcomes considered during development of current dietary reference values for calcium and/or vitamin D, compiled from^(3,8,14,15,41). COVID-19, coronavirus disease-19.

necessary because of physiological adaptive processes in the mother, such as enhanced intestinal absorption and renal conservation, or because the extra requirement is offset by reduction in needs elsewhere. An example of the former is calcium in pregnancy, when the calcium requirement for fetal growth is met by increases in maternal intestinal absorption and mobilisation of skeletal mineral (discussed in more detail later), and, of the latter, is iron in pregnancy, where the extra requirement for fetal growth is offset by cessation of menstruation in the mother.

Requirements for calcium and vitamin D

Functional outcomes and disease risk reduction

As described earlier, there has been much interest in recent years in developing micronutrient DRV based on functional outcomes, intermediate health markers and disease risk reduction, especially where emerging research has suggested that greater amounts of the micronutrient might be required to prevent deficiency. Two interdependent micronutrients that have attracted much attention in this regard are calcium and vitamin D. Both are essential for skeletal growth and health, at all stages of the lifecourse from fetal life to old age. Classically, the requirements for these micronutrients have been based on their importance for the skeletal system. Calcium is a primary bone-forming mineral and 98–99% body content of calcium is in the skeleton. Vitamin D, through its metabolites 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D, is involved in the control of intestinal absorption, renal conservation and skeletal metabolism of calcium and other related minerals. However, 1–2% calcium is widespread throughout the body, where it has essential cellular

functions, and 1,25-dihydroxyvitamin D is important in the control of many genomic and other cellular processes. On this basis, the possibility that low intakes of calcium and/or poor vitamin D status are implicated in a wide range of non-skeletal conditions and chronic diseases has been proposed by many research groups and has been considered by the DRV Committees in recent years (Fig. 1). As there are known differences in the prevalence of many of these health outcomes between males and females, this might signal that the requirements for calcium and vitamin D may differ by sex. However, to date, the results of trials and other robust studies investigating these possibilities have either not indicated the anticipated health advantages, or, where there are links, these are generally not at calcium intakes or plasma 25(OH)D concentrations (the biomarker of vitamin D status) above those recommended on the basis of skeletal outcomes. As yet, none of the potential health outcomes listed in Fig. 1 has been used for DRV development, except for muscle weakness/falls for vitamin D e.g.⁽³⁾.

Sex differences in calcium requirements and dietary reference values

Because there is no recognised specific indicator or biomarker of calcium adequacy, bone mineral content (BMC), bone mineral density (BMD), bone health and fracture risk are considered the main health outcomes for this micronutrient, whereas DRV development is generally based on calcium retention estimated on theoretical grounds from reference data or measured empirically in balance studies. The factorial method is used for children and adolescence, whereby the calcium retention at each age required for skeletal mineral accretion is combined with estimates of calcium absorption

Table 3. Dietary reference values for calcium (mg/d)

Lifestage	UK*		USA/Canada†			EU‡		
	Males	Females	Lifestage	Males	Females	Lifestage	Males	Females
Children								
1–3 years	350	350	1–3 years	700	700	1–3 years	450	450
4–6 years	450	450	4–8 years	1000	1000	4–10 years	800	800
7–10 years	550	550						
Adolescents								
11–14 years	1000	800	9–13 years	1300	1300	11–17 years	1150	1150
15–18 years	1000	800	14–18 years	1300	1300	18–24 years	1000	1000
Adults								
19–50 years	700	700	19–50 years	1000	1000	≥25 years	950	950
50+ years	700	700	51–70 years	1000	1200			
			>70 years	1200	1200			
Pregnancy and lactation								
Pregnancy		+0	Pregnancy		+0	Pregnancy		+0
Lactation§		+550§	Lactation		+0	Lactation		+0

* Reference nutrient intake, developed and published by the Committee on the Medical Aspects of Food Policy 1991⁽²⁾ and re-evaluated and endorsed in 1998⁽¹⁴⁾.

† RDA, developed and published by the Institute of Medicine 2011⁽⁸⁾.

‡ Population reference intake, developed and published by the European Food Safety Authority 2015⁽⁴¹⁾.

§ Lactation for 0–4 months and >4 months; indicated in 1998 that the increment 'may not be necessary'⁽¹⁴⁾.

from a diet typical of the population (usually about 30% in Western countries) and losses in urine, faeces and sweat to provide an average dietary requirement on which the DRV are derived (Table 1). Calcium retention is estimated from reference BMC/BMD and growth data and from calcium balance studies. In theory, therefore, because boys are taller than girls on average at the same age, with bigger skeletons, there is an expectation of sex differences in skeletal calcium accretion and thus in the DRV for children and adolescents. To date, none of the three DRV Committees have recommended different calcium DRV for boys and girls, except by the UK for ages 11–18 years (Table 3). Averaged data are used at each age. This implies that more boys than girls will exceed the 97.5 percentile on the average distribution of requirements, meaning that the needs of more than 2.5% of the tallest boys might not be met by the RNI (but fewer than 2.5% of girls), whereas more girls than boys will fall under the 2.5 percentile on the average distribution, resulting in an overestimate of girls and an underestimate of boys with a requirement not met by the lower RNI (a risk indicator in the UK).

Similar considerations pertain to the calcium requirements for adult men and women, with values based primarily on calcium retention from balance studies. Osteoporotic fracture risk and bone mineral loss increase in later life are greater among women than men, especially during the menopause. In the past, there was a presumption that this reflects a degree of calcium deficiency and therefore that calcium requirements increase with age and are greater in women. However, in general, the results of randomised trials and other studies have not borne this out e.g.^(11,12). Associations between BMC/BMD, fracture risk and customary diet within populations are inconsistent, and on a world-wide basis, populations with a lower risk of osteoporotic fracture are ones with lower customary calcium intake⁽¹³⁾. The

evidence is further complicated by the fact that calcium is an antiresorptive agent i.e. it reduces the rate of bone resorption during bone remodelling cycles⁽¹³⁾. Increases in calcium intake, generally by using supplements, therefore produce a measurable but small increase in BMC and BMD for a period of time, a phenomenon known as a bone remodelling transient, but do not slow the rate of bone loss⁽¹³⁾. The use of calcium supplementation to reduce bone resorption at times of bone loss can, therefore, be considered more a pharmacological intervention than a correction of dietary deficiency. None of the three DRV Committees felt able to use BMC/BMD or fracture risk as criteria for setting DRV for calcium^(2,8,14,15). However, the IoM did include an increment above the young adult value for menopausal women of 200 mg Ca/d to 'err on the side of caution' in recognition of the effects of an increase in calcium intake on BMD at this stage of life, thereby introducing a sex difference in the USA/Canadian dietary reference intake⁽⁸⁾. They also applied the same increment for both men and women >70 years of age (Table 3).

Calcium is essential for fetal growth and breast-milk production at amounts within the distribution of maternal calcium intakes⁽¹⁶⁾. This raises the possibility that women of reproductive age have higher dietary calcium requirements during pregnancy and lactation than other adults. However, it has been recognised for many years that women in populations with a low calcium intake can have many cycles of pregnancy and lactation without apparent calcium deficiency or detriment to their long-term bone health^(2,17). Physiological adaptations including increased intestinal calcium absorption, mobilisation of bone mineral and, in lactation, renal calcium conservation appear to provide sufficient calcium to meet these requirements without requiring greater dietary calcium intake by the mother^(16,18). This is discussed in more detail later.

Sex differences in vitamin D requirements and dietary reference values

Unlike other micronutrients, vitamin D can be synthesised in the skin by the action of UV light B contained in sunlight. A dietary source of vitamin D is required to maintain good vitamin D status when skin UV light B exposure is limited or sunlight contains little or no UV light B, such as during the winter in temperate countries. In such circumstances, certain population sub-groups are especially vulnerable to limited skin synthesis and poor vitamin D status. The provision of DRV for vitamin D is to achieve vitamin D sufficiency across the population in all groups. The biomarker of vitamin D status is the circulating metabolite 25(OH)D, and the concentration of 25(OH)D below which there is an increased risk of rickets and osteomalacia is used as the main criterion for DRV development for vitamin D, combined with judgements about other aspects of musculoskeletal health such as BMC/BMD, muscle strength, falls, fracture risk and calcium absorption. The dietary intake required to achieve the selected 25(OH)D concentration in the absence of UV light B skin exposure is then used to develop the DRV, using data from supplementation and dose-ranging studies. In general, these studies show that children, adolescents and older persons require similar dietary intakes of vitamin D over a period of time to achieve specific 25(OH)D concentrations with no indication of any difference by sex. Consequently, in each of the three sets of DRV, although different threshold values of 25(OH)D concentration may have been selected for DRV development resulting in different recommended intakes of vitamin D, the same values apply to both males and females and at all stages of the lifecourse except for infancy. The exception is that IoM added an increment to the dietary reference intake for both men and women >70 years, an approach 'predicated on caution in the face of uncertainties'⁽⁸⁾ relating to vitamin D intake and fracture risk in older adults.

The same considerations apply to women during pregnancy and lactation, and none of the three DRV committees considered that increasing the DRV above that of adults is necessary. However, recent studies suggest that there may be benefits of a higher dietary intake of vitamin D by women during pregnancy and lactation than those currently recommended to boost neonatal and infant vitamin D status, and potentially improve maternal and offspring health outcomes^(19–21). This is a topic of current controversy⁽²¹⁾ and is discussed more fully elsewhere⁽²²⁾.

Sex-specific findings in Gambian and UK studies of calcium requirements

The Gambia, West Africa, has a diet typical of many around the world where milk and milk products are rarely consumed or are in short supply⁽¹³⁾. Calcium intakes in the resource-poor rural regions of The Gambia are very low, averaging three to four times less than those indicated by the DRV of the UK, USA/Canada and European Food Safety Authority⁽²³⁾. The MRC Nutrition and Bone Health Group has conducted detailed studies over many years, to provide evidence of

the health benefits for the people of The Gambia of a higher calcium intake^(14,24–39). This has been through randomised, placebo controlled trials with long-term follow-up and longitudinal cohort studies, complemented by similar investigations using identical methods and technologies in Cambridge, UK. These have generally not demonstrated the anticipated benefits of higher calcium intakes but, instead, have shown some unforeseen, sex-specific effects with potential consequences for health.

An early trial by this group in lactating Gambian women, who were supplemented for 12 months from 2 weeks postpartum with 1000 mg Ca/d as calcium carbonate or placebo, was designed to determine the effect on maternal BMC/BMD, biochemical markers of bone turnover, breast-milk calcium content and infant growth⁽²⁴⁾. No significant differences were observed between the mothers and infants in the supplemented and placebo groups for these outcomes. There was, however, evidence in both groups of mothers of bone mineral mobilisation in the first months postpartum with restoration later in lactation, in a similar way to lactating women in Cambridge^(24,25). These findings added to the accumulating evidence at that time that bone mobilisation is a physiological aspect of lactation and that breast-milk calcium content is not responsive to maternal calcium intake^(26–28). These studies formed part of the evidence that an increase in dietary calcium intake is not necessary during lactation⁽¹⁴⁾. DRV for women developed since that time are the same as those for women and men of the same age (Table 3).

A subsequent trial of pregnant women, who were supplemented from 20 weeks of gestation to delivery with 1500 mg Ca/d as calcium carbonate or placebo, was designed to determine the effects of the higher calcium intake on maternal blood pressure and offspring size at birth, and on postpartum maternal and infant BMC/BMD, breast-milk calcium content and infant growth^(29–31). None of the anticipated benefits were found, as there were no significant differences between the groups in maternal blood pressure, breast-milk calcium content or fetal and infant growth^(29,31). Unexpectedly, however, those women who had received the calcium supplement in pregnancy exhibited greater bone mobilisation postpartum than those in the placebo group⁽³⁰⁾. In a follow-up study of the mothers after approximately 5 years when the women were neither pregnant nor breast-feeding, we showed the expected restoration of BMC/BMD in the mothers in the placebo group but not in those who had received the calcium supplement⁽³²⁾. This opens the possibility that, rather than a benefit, the increase in calcium intake during pregnancy may have had a negative effect on the mother's long-term bone health. To investigate this possibility, a further set of measurements after approximately 20 years has recently been completed, currently under analysis, to determine the impact of calcium supplementation in pregnancy on maternal bone health in mid-life.

Unexpected results have also emerged from follow-up studies of the offspring of these mothers during childhood and adolescence^(33,34). These have demonstrated significant sex-specific effects of the maternal supplement on

pre-pubertal child growth and bone development at age 8–12 years, such that those girls whose mothers had received the calcium supplement in pregnancy were shorter, lighter and with smaller bones with less bone mineral than girls whose mothers had been in the placebo group. The effects in the boys were the converse, with those whose mothers had received the pregnancy calcium supplement tending to be larger with greater bone mineral than boys whose mothers had been in the placebo group⁽³⁴⁾. These effects on growth and bone development were associated with the corresponding sex-specific effects of the maternal supplement on offspring plasma insulin-like growth factor 1 concentration in mid-childhood⁽³³⁾. This suggested that the calcium carbonate supplement had altered the *in utero* programming of the offspring growth hormone–insulin-like growth factor 1 axis differently in boys and girls, an effect which might be expected to result in sex-specific effects on the timing of puberty and on adolescent growth of the offspring. This possibility is being investigated in continuing follow-up studies.

Such possibilities have also been suggested by the results of supplementation trials and follow-up studies of pre-pubertal children in The Gambia^(35,36) and of adolescents in Cambridge⁽³⁷⁾. Gambian boys who participated in a supplementation trial at age 8–12 years, using 750 mg Ca/d calcium carbonate or placebo, entered their pubertal height spurt earlier if they had previously received the calcium supplement than boys in the placebo group⁽³⁵⁾. As a result, the boys in the calcium group were taller in mid-adolescence compared to the placebo group, but they stopped growing earlier and were shorter in young adulthood, with similar effects on the timing of bone development^(35,36). No such effects were observed in the girls^(35,36). In Cambridge, 12–15 months of supplementation with 1000 mg Ca/d as calcium carbonate resulted in greater height and skeletal size but no effect on BMC after size-adjustment in 16–18-year-old boys compared to placebo, whereas the calcium supplement resulted in greater size-adjusted BMC but not stature in girls^(38,39). In both Cambridge trials the calcium supplement was associated with an increase in the circulating concentration of insulin-like growth factor 1⁽³⁷⁾. The effect of the calcium carbonate supplementation is likely to represent increased bone growth in the boys and a bone remodelling transient in the girls, similar to that described earlier for perimenopausal women. In both the Gambian and Cambridge studies, the girls may have been at a later stage of skeletal maturation than the boys at the start of the trials, which may account for some of the sex-specific differences observed. This is because there is a discordance between boys and girls in the timing of pubertal changes and in the cessation of linear growth caused by fusion of the epiphyses at the ends of long bones, with girls maturing at earlier ages than boys.

Studies such as these suggest the possibility that boys and girls may have subtly different calcium requirements, and that these may be influenced by maternal calcium intake during pregnancy, by changes in calcium intake during childhood and adolescence and by the timing of any intervention relative to the various hormonal and skeletal changes that occur between conception and

adulthood. These effects may be due to alterations in the trajectories of growth, resulting in changes to the timing of the pubertal growth spurt and potentially affecting adult size and skeletal characteristics.

DRV are designed to meet the needs of healthy individuals, including pregnant women, when all other nutrient requirements are met, to prevent insufficiency. Calcium supplements are also prescribed medically to treat certain conditions, such as menopausal and age-related osteoporosis, usually as an adjunct to other medications. The WHO currently recommends pregnant women in populations with a low calcium intake to take a calcium supplement of 1500–2000 mg/d to prevent pre-eclampsia and its complications, based on the results of several randomised controlled trials⁽⁴⁰⁾. To date, there have been no studies to investigate whether this population-based recommendation has long-term consequences for maternal bone health or offspring growth and development similar to the effects observed in the Gambian studies.

Conclusions

Sex differences in micronutrient requirements that are reflected in DRV guidelines are mostly to cover differences in body size or macronutrient intakes, although often average values for males and females are given. To date, little account has been taken of more subtle effects on sex differences in growth and maturation rates, health vulnerabilities or *in utero* and other programming effects. Future research may allow more nuanced sex-specific guidelines. These need to consider potential disadvantages and harms as well as benefits of intakes of micronutrients above those currently consumed by apparently healthy people, and to evaluate possible long-term metabolic consequences on body systems not related to the primary outcome of interest. As studies by the MRC Nutrition and Bone Health Group of calcium requirements in The Gambia and Cambridge have suggested, more is not necessarily better. For the present, however, with the limited evidence available for most micronutrients, current DRV values provide the best estimate of population dietary requirements, thereby ensuring adequacy for the majority of individuals, and the provision of average DRV for males and females simplifies, and therefore strengthens, public health messages.

Acknowledgements

I gratefully acknowledge the contributions of the study participants and of all members and supporting staff, past and present, of the MRC Nutrition and Bone Health Group in Cambridge and the Calcium, Vitamin D and Bone Health Group in The Gambia.

Financial Support

The Gambian and Cambridge studies described in the present paper were supported by Medical Research

Council (Programmes U105960371, U123261351 and MC-A760-5QX00) and the Department for International Development (DfID) under the MRC/DfID Concordat. Where there was additional funding for individual components of these studies, they are listed in the published papers cited.

Conflicts of Interest

None.

Authorship

The author had sole responsibility for all aspects of preparation of this paper.

References

1. Powers HJ (2021) Approaches to setting dietary reference values for micronutrients, and translation into recommendations. *Proc Nutr Soc* (In the Press).
2. Department of Health (1991) *Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy*. vol. 41, *Report on Health and Social Subjects*. London: Her Majesty's Stationery Office.
3. Scientific Advisory Committee on Nutrition (2016) Vitamin D and Health. <https://www.gov.uk/government/groups/scientific-advisory-committee-in-nutrition>.
4. Institute of Medicine (1998) *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline*. Washington, DC: National Academy Press.
5. Institute of Medicine (2000) *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*. Washington, DC: National Academy Press.
6. Institute of Medicine (2001) *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington, DC: National Academy Press.
7. Institute of Medicine (1997) *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. Washington, DC: National Academy Press.
8. Institute of Medicine Food and Nutrition Board (2011) *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: The National Academies Press.
9. National Academies of Sciences Engineering and Medicine (2019) *Dietary Reference Intakes for Sodium and Potassium*. Washington, DC: The National Academies Press.
10. European Food Standards Authority (2017) *Dietary Reference Values for Nutrients: Summary Report*. EFSA Supporting Publication. Available at <https://www.efsa.europa.eu/en/supporting/pub/e15121>
11. Kahwati LC, Weber RP, Pan H *et al.* (2018) Evidence report and systematic review for the US preventive services task force. *JAMA* **319**, 1600–1612.
12. Uusi-Rasi K, Kärkkäinen MU & Lamberg-Allardt CJ (2013) Calcium intake in health maintenance. *Food Nutr Res* **57**, 21082.
13. Prentice A (2004) Diet, nutrition and the prevention of osteoporosis. *Public Health Nutr* **7**, 227–243.
14. Department of Health (1998) *Nutrition and Bone Health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food and Nutrition Policy*. vol. 49, *Report on Health and Social Subjects*.
15. European Food Standards Authority Panel on Dietetic Products Nutrition and Allergies (2016) Scientific opinion on dietary reference values for vitamin D. *EFSA J* **14**, 1–145.
16. Prentice A (2011) Pregnancy and lactation. In *Pediatric Bone: Biology and Diseases*, 2nd ed. Chapter 1, pp. 1–25 [Glorieux FH, Pettifor JM and Juppner H, editors]. Chennai, India: Elsevier.
17. Walker ARP, Richardson B & Walker F (1972) The influence of numerous pregnancies and lactations on bone dimensions in South African bantu and Caucasian mothers. *Clin Sci* **42**, 189–196.
18. Olausson H, Goldberg GR, Laskey MA *et al.* (2012) Calcium economy in human pregnancy and lactation. *Nutr Res Rev* **25**, 40–67.
19. O'Callaghan KM, Hennessy A, Hull GLJ *et al.* (2016) Estimation of the maternal vitamin D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a concentration sufficient to keep umbilical cord sera ≥ 25 –30 nmol/L: a dose-response, double-blind, randomized placebo-controlled trial in pregnant women at northern latitude. *Am J Clin Nutr* **108**, 77–91.
20. Wagner CL & Hollis BW (2020) Early-life effects of vitamin D: focus on pregnancy and lactation. *Ann Nutr Metab* **76**(Suppl. 2), 16–28.
21. Kiely ME, Wagner CL & Roth DE (2020) Vitamin D in pregnancy: where we are and where should we go. *J Steroid Biochem Mol Biol* **201**, 105669.
22. Kiely ME (2021) Risk factors and health impacts of vitamin D, iron and iodine deficiencies in pregnancy. *Proc Nutr Soc* (In the Press).
23. Prentice A (2007) Studies of Gambian and UK children and adolescents: Insights into calcium requirements and adaptation to a low calcium intake. In *Nutritional Aspects of Osteoporosis 2006*, International Congress Series, pp. 15–24 [P Burckhardt, B Dawson-Hughes and RP Heaney, editors]. Amsterdam: Elsevier.
24. Prentice A, Jarjou LMA, Cole TJ *et al.* (1995) Calcium requirements of lactating Gambian mothers: effects of a calcium supplement on breastmilk calcium concentration, maternal bone mineral content, and urinary calcium excretion. *Am J Clin Nutr* **62**, 58–67.
25. Laskey MA, Prentice A, Hanratty LA *et al.* (1998) Bone changes after 3 mo of lactation: influence of calcium intake, breast-milk output, and vitamin D-receptor genotype. *Am J Clin Nutr* **67**, 685–692.
26. Prentice A (1997) Calcium supplementation during breast-feeding. *N Eng J Med* **337**, 558–559.
27. Laskey A & Prentice A (1999) Bone mineral changes during and after lactation. *Obstet Gynecol* **94**, 608–615.
28. Prentice A, Laskey MA & Jarjou LMA (1999) Lactation and bone development: implications for the calcium requirements of infants and lactating mothers. In *Nutrition and Bone Development*, pp. 127–145 [J-P Bonjour and R Tsang, editors]. Philadelphia: Vestey/Lippincott-Raven Publishers.
29. Jarjou LMA, Prentice A, Sawo Y *et al.* (2006) Randomized, placebo-controlled calcium supplementation study of pregnant Gambian women: effects on breast-milk calcium concentrations and infant birth weight, growth and



- bone mineral accretion in the first year of life. *Am J Clin Nutr* **83**, 657–666.
30. Jarjou LMA, Laskey MA, Sawo Y *et al.* (2010) Effect of calcium supplementation in pregnancy on maternal bone outcomes among women with a low calcium intake. *Am J Clin Nutr* **92**, 450–457.
 31. Goldberg GR, Jarjou LMA, Cole TJ *et al.* (2013) Randomized, placebo-controlled, calcium supplementation trial in pregnant Gambian women accustomed to a low calcium intake: effects on maternal blood pressure and infant growth. *Am J Clin Nutr* **98**, 972–982.
 32. Jarjou LMA, Sawo Y, Goldberg GR *et al.* (2013) Unexpected long-term effects of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake: a follow-up study. *Am J Clin Nutr* **98**, 723–730.
 33. Prentice A, Ward KA, Nigdikar S *et al.* (2019) Pregnancy supplementation of Gambian mothers with calcium carbonate alters mid-childhood IGF1 in a sex-specific manner. *Bone* **120**, 314–320.
 34. Ward KA, Jarjou L & Prentice A (2017) Long-term effects of maternal calcium supplementation on childhood growth differ between males and females in a population accustomed to a low calcium intake. *Bone* **103**, 31–38.
 35. Prentice A, Dibba B, Sawo Y *et al.* (2012) The effect of prepubertal calcium carbonate supplementation on the age of peak height velocity in Gambian adolescents. *Am J Clin Nutr* **96**, 1042–1050.
 36. Ward KA, Cole TJ, Laskey MA *et al.* (2014) The effect of prepubertal calcium carbonate supplementation on skeletal development in Gambian boys – a 12 year follow-up study. *J Clin Endocrinol Metab* **99**, 3169–3176.
 37. Ginty F, Prentice A, Laidlaw A *et al.* (2004) *Calcium Carbonate Supplementation is Associated with Higher Plasma IGF-1 in 16–18 Year old Boys and Girls, Nutritional Aspects of Osteoporosis*, 2nd ed. Lausanne, Switzerland: Elsevier Science (USA).
 38. Stear SJ, Prentice A, Jones SC *et al.* (2003) Effect of a calcium and exercise intervention on the bone mineral status of 16–18-y-old adolescent girls. *Am J Clin Nutr* **77**, 985–992.
 39. Prentice A, Ginty F, Stear SJ *et al.* (2005) Calcium supplementation increases stature and bone mineral mass of 16–18 year old boys. *J Clin Endocrinol Metab* **90**, 3153–3161.
 40. World Health Organization (2018) *WHO recommendation: Calcium Supplementation During Pregnancy for the Prevention of pre-Eclampsia and its Complications*. Geneva: World Health Organization.
 41. European Food Standards Authority Panel on Dietetic Products Nutrition and Allergies (2015) Scientific opinion on dietary reference values for calcium. *EFSA J.* Available at <https://www.efsa.europa.eu/en/efsajournal/pub/4101>